Crossref
Intravenous vitamin C for COVID-19: no benefit
Drug and Therapeutics Bulletin · 2024
DOI: 10.1136/dtb.2024.000055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, 2024. Hauptthemen laut MEDLINE: Ascorbic Acid, COVID-19 Drug Treatment, Administration, Intravenous. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Overview of: LOVIT-COVID Investigators. Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials. JAMA 2023;330:1745-59.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Ascorbic AcidCOVID-19 Drug TreatmentAdministration, IntravenousHumansRandomized Controlled Trials as TopicCOVID-19SARS-CoV-2Vitamins
Stichwörter der Autor:innen
Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation
Substanzen
Ascorbic AcidVitamins
Zitieren
APA
(2024). Intravenous vitamin C for COVID-19: no benefit. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2024.000055
Vancouver
Intravenous vitamin C for COVID-19: no benefit. Drug and Therapeutics Bulletin. 2024. doi:10.1136/dtb.2024.000055
BibTeX
@article{euvimed2024,
title = {Intravenous vitamin C for COVID-19: no benefit},
journal = {Drug and Therapeutics Bulletin},
year = {2024},
doi = {10.1136/dtb.2024.000055}
}
EUVIMED